AstraZeneca PLC (AZN)
| Market Cap | 255.02B +3.0% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.41 |
| Forward PE | 15.19 |
| Dividend | $3.23 (1.96%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 2,425,271 |
| Open | 165.64 |
| Previous Close | 161.63 |
| Day's Range | 162.24 - 165.74 |
| 52-Week Range | 146.10 - 212.71 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 212.54 (+28.99%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AZN stock is "Strong Buy." The 12-month stock price target is $212.54, which is an increase of 28.99% from the latest price.
News
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power
AMD, Costco and AstraZeneca headline Zacks' latest research, with AI demand, membership strength and new drugs shaping their outlooks.
Top Stock Reports for AMD, Costco & AstraZeneca
AMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.
AZN Looks 10.6% Undervalued on GF Value⢠as Dividend Remains Sustainable
AZN Looks 10.6% Undervalued on GF Value⢠as Dividend Remains Sustainable
AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win
AstraZeneca's $80 Billion Plan Gets Another Tagrisso Win
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Secure
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Secure
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.5% Undervalued on GF Value⢠as Dividend Remains Attractive
AZN Looks 10.5% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AZN Looks 10.5% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AstraZeneca completes global license agreement for Zegfrovy in lung cancer
AstraZeneca (AZN) announced the completion of the exclusive license agreement with Dizal Pharmaceutical for Zegfrovy – sunvozertinib -, an oral irreversible epidermal growth factor receptor, or EGFR, ...
NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier
Pharmaceutical industry leader brings more than 20 years of global drug development, regulatory strategy and portfolio leadership experience across AbbVie, Merck KGaA, AstraZeneca and Abivax TORONTO, ...
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvo...
AstraZeneca announces Tagrisso, Orpathys demonstrated ‘meaningful improvement’
Positive high-level results from the SANOVO Phase III trial showed Tagrisso plus Orpathys demonstrated a statistically significant meaningful improvement in progression-free survival, PFS, versus Tagr...
AstraZeneca completes exclusive license agreement with Dizal for Zegfrovy
AstraZeneca (AZN) announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical for Zegfrovy, an oral irreversible epidermal growth factor recep...
AZN Looks 10.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 10.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AstraZeneca And Daiichi Sankyo Gain EU Nod For Enhertu Plus Pertuzumab In HER2+ Breast Cancer
(RTTNews) - AstraZeneca (AZN) and Daiichi Sankyo announced that the European Commission has approved Enhertu in combination with Pertuzumab for the treatment of adult patients with HER2-positive metas...
Daiichi Sankyo, AstraZeneca announce Enhertu combination approval in the EU
Enhertu in combination with pertuzumab has been approved in the European Union for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. Enhertu is a…
AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said positive high-level results from the SANOVO Phase III trial in China demonstrated Tagrisso plus Orpathys showed a statistically significant an...
AstraZeneca lung cancer therapy combination shows promise in advanced study
AstraZeneca said on Tuesday that a Chinese late-stage trial of a combination of its cancer drugs Tagrisso and Orpathys significantly improved progression-free survival when given as a first...
AZN Looks 9.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 9.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AstraZeneca gets FDA orphan designation for treatment of esophageal cancer
AstraZeneca (AZN) Pharmaceuticals’ sonesitatug vedotin was granted FDA orphan designation as a treatment of esophageal cancer, according to a post to the agency’s website.
AZN Looks 9.3% Undervalued on GF Value⢠Amid Dividend Sustainability
AZN Looks 9.3% Undervalued on GF Value⢠Amid Dividend Sustainability
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented at the E...
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
After Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN) presented full results of the Cardio-TTRansform trial at the ESC Congress 2026 in Munich, Jefferies said the data came in “mostly as expected.”...
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success
AstraZeneca FTSE Shares: Is AZN the Right Foundation for a £10k Portfolio?
AstraZeneca FTSE shares are among the first names that come up when beginners consider building a £10,000 portfolio in 2026, and the latest half-year results go some way to explaining why. Total reven...
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.